Jazz Pharmaceuticals JAZZ reported third-quarter 2025 adjusted earnings per share (EPS) of $8.13 per share, beating the Zacks Consensus Estimate of $5.74. This beat was largely due to an income tax ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback